Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson XARELTO (rivaroxaban) by Year
XARELTO (rivaroxaban) — Worldwide currency (FX) impact YoY (%) (%)
Johnson & Johnson XARELTO (rivaroxaban): 0.3% in FY2025, up 1.4 pts from a year earlier.
Latest, FY2025
0.3%
Period ended Dec 28, 2025
Change on a year earlier
+1.4 pts
-1.1% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| WW | 1,145 | 1,189 | (3.7) | (4.0) | 0.3”
Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | XARELTO (rivaroxaban) — Worldwide currency (FX) impact YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 0.3% | +1.4 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | -1.1% | -0.9 pts | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
| FY2023 | Dec 31, 2023 | -0.2% | – | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson XARELTO (rivaroxaban) (%), annual FY2023–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-xarelto-fx-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.